## **Core Concept**
P-Glycoprotein (P-gp) is a transmembrane protein that acts as an efflux pump, playing a crucial role in reducing the intracellular concentration of various drugs, thereby affecting their efficacy. Inhibitors of P-glycoprotein can increase the bioavailability and tissue retention of drugs that are P-gp substrates.

## **Why the Correct Answer is Right**
is known to be a potent inhibitor of P-glycoprotein. By inhibiting P-gp, it prevents the efflux of drugs that are substrates for this pump, leading to increased intracellular drug concentrations. This mechanism is significant in the context of cancer treatment, as it can help overcome multidrug resistance.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is not identified as a P-glycoprotein inhibitor; its primary action or classification might be different.
* **Option B:** does not function as a P-glycoprotein inhibitor; it may have other pharmacological effects.
* **Option C:** is not recognized for its P-glycoprotein inhibitory activity.

## **Clinical Pearl / High-Yield Fact**
A significant clinical implication of P-glycoprotein inhibition is the potential to overcome multidrug resistance in cancer therapy. Clinicians should be aware that co-administration of P-gp inhibitors with certain chemotherapeutic agents can enhance drug efficacy but may also increase toxicity.

## **Correct Answer:** . Verapamil